Pancreatic cancer

Role of single nucleotide polymorphisms of DNA repair genes in susceptibility to pancreatic cancer in Chinese population

M. F. Ying, Zhao, R., Ying, M. F., Zhao, R., Ying, M. F., and Zhao, R., “Role of single nucleotide polymorphisms of DNA repair genes in susceptibility to pancreatic cancer in Chinese population”, vol. 15, p. -, 2016.

We conducted a case-control study to investigate the role of ERCC1-ERCC5 gene polymorphisms in the risk of pancreatic cancer. This study included 195 patients who were newly diagnosed with histopathologically confirmed primary pancreatic cancer, and 254 controls were recruited from Sir Run Run Shaw Hospital, between January 2012 and December 2014. Genotyping of ERCC1 rs3212986 and rs11615, ERCC2 rs13181, ERCC3 rs4150441, ERCC4 rs6498486, and ERCC5 rs2094258 polymorphisms was carried out using polymerase chain reaction coupled with restriction fragment length polymorphism.

Effects of gemcitabine on radiosensitization, apoptosis, and Bcl-2 and Bax protein expression in human pancreatic cancer xenografts in nude mice

Z. T. Shen, Wu, X. H., Wang, L., Li, B., and Zhu, X. X., “Effects of gemcitabine on radiosensitization, apoptosis, and Bcl-2 and Bax protein expression in human pancreatic cancer xenografts in nude mice”, vol. 14, pp. 15587-15596, 2015.

The aim of this study was to evaluate the radiosensitizing effects of gemcitabine towards human pancreatic cancer xenografts. A human pancreatic cancer xenograft model was established in nude mice, 36 of which were randomly divided into 6 treatment groups. Tumors were measured every 2 days, and the tumor volumes, growth delays, and inhibition rates were compared to evaluate the gemcitabine enhancement factor.

MicroRNA-215 functions as a tumor suppressor and directly targets ZEB2 in human pancreatic cancer

Q. W. Li, Zhou, T., Wang, F., Jiang, M., Liu, C. B., Zhang, K. R., Zhou, Q., Tian, Z., and Hu, K. W., “MicroRNA-215 functions as a tumor suppressor and directly targets ZEB2 in human pancreatic cancer”, vol. 14, pp. 16133-16145, 2015.

It has been shown that microRNA-215 (miR-215) is dysregulated in several human malignancies, and this correlates with tumor progression. However, its expression and function in pancreatic cancer is still unclear. The aim of this study was to explore the effects of miR-215 on pancreatic cancer formation and progression. Using quantitative RT-PCR, we detected miR-215 expression in pancreatic cancer cell lines and primary tumor tissues. The association of miR-215 expression with clinicopathological factors and prognosis was also analyzed.

Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis

B. - S. Li, Liu, H., and Yang, W. - L., “Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis”, vol. 14, pp. 16372-16378, 2015.

microRNA-218 (miR-218) is a vertebrate-specific miRNA that plays a crucial role in tumorigenesis and tumor progression. This study analyzed the miR-218 expression level and clinical significance in pancreatic cancer. One hundred and seven pairs of pancreatic cancer and adjacent normal tissues were analyzed by quantitative reverse-transcriptase polymerase chain reaction. The correlation between miR-218 expression and clinicopathological characters was determined by the two-sample Student t-test.

Association between N-acetyltransferase 2 polymorphisms and pancreatic cancer risk: a meta-analysis

J. X. Liang, Gao, W., Liang, Y., and Zhou, X. M., “Association between N-acetyltransferase 2 polymorphisms and pancreatic cancer risk: a meta-analysis”, vol. 14, pp. 17219-17227, 2015.

N-acetyltransferase 2 (NAT2) is an essential phase II enzyme in the metabolism of aromatic and heterocyclic amines and of hydrazines. NAT2 activity can be divided into three phenotypes: rapid, intermediate, and slow. Studies identifying an association between NAT2 polymorphism and the risk of pancreatic cancer have shown conflicting results.

Correlation of miR-494 expression with tumor progression and patient survival in pancreatic cancer

Y. B. Ma, Li, G. X., Hu, J. X., Liu, X., and Shi, B. M., “Correlation of miR-494 expression with tumor progression and patient survival in pancreatic cancer”, vol. 14, pp. 18153-18159, 2015.

MicroRNA-494 (miR-494) expression is aberrant in various types of human cancer. However, the prognostic value of miR-494 in pancreatic cancer remains unclear. The level of miR-494 expression was determined in 99 pairs of primary pancreatic cancer and their corresponding, adjacent non-tumor tissues by using quantitative reverse transcriptase polymerase chain reaction. We also analyzed the associations between miR-494 expression and clinicopathological features. The survival correlations were analyzed by using the Kaplan-Meier method and Cox proportional hazards model.

Propofol suppresses proliferation and invasion of pancreatic cancer cells by upregulating microRNA-133a expression

Z. T. Wang, Gong, H. Y., Zheng, F., Liu, D. J., and Dong, T. L., “Propofol suppresses proliferation and invasion of pancreatic cancer cells by upregulating microRNA-133a expression”, vol. 14, pp. 7529-7537, 2015.

Propofol is a commonly used intravenous anesthetic. We evaluated its effects on the behavior of human pancreatic cancer cells and the underlying molecular mechanisms. The effects of propofol on Panc-1 cell proliferation, apoptosis, and invasion were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, caspase-3 activity measurement, and Matrigel invasion assay. Quantitative polymerase chain reaction (qPCR) was used to assess microRNA-133a (miR-133a) expression.

Association between single nucleotide polymorphisms of X-ray repair cross-complementing protein 4 gene and development of pancreatic cancer

Y. Ding and Li, L. N., “Association between single nucleotide polymorphisms of X-ray repair cross-complementing protein 4 gene and development of pancreatic cancer”, vol. 14, pp. 9626-9632, 2015.

We performed a study to evaluate X-ray repair cross-complementing protein 4 (XRCC4) gene polymorphisms and the development of pancreatic cancer. A case-control study including 206 patients with newly diagnosed primary pancreatic cancer and 412 controls was performed between January 2011 and October 2013 in a Chinese population. Genotypes of XRCC4 rs1805377, rs2075685, rs2075686 and rs1056503 were determined using polymerase chain reaction combined with a restriction fragment length polymorphism assay.

Subscribe to Pancreatic cancer